Sarepta Therapeutics SRPT
$13.33 −$0.84 (-5.93%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $13.60 +2.03%
Open$13.92
Prev close$14.17
Day range$13.25 – $14.47
Volume2.25M
Market cap$1.43B
P/E (TTM)–
Dividend yield–
SRPT Stock News
Headlines matching Sarepta Therapeutics or the SRPT ticker, most recent first.
- J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Announces Target Price $20
- William Blair Initiates Sarepta Therapeutics(SRPT.US) With Hold Rating
- Citi Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $13
- Needham Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating
- J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Raises Target Price to $23 Positive
- J.P. Morgan Remains a Hold on Sarepta Therapeutics (SRPT)
- J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating
- Barclays Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $20
- A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $5 to $38
- Evercore Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $19
- Wolfe Research Upgrades Sarepta Therapeutics(SRPT.US) to Buy Rating, Announces Target Price $27 Positive
- Analysts' Opinions Are Mixed on These Healthcare Stocks: Vericel (VCEL), Sarepta Therapeutics (SRPT) and Neumora Therapeutics, Inc. (NMRA)
- Morgan Stanley Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $25
- Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $31
- Tradr 2X Long SRPT Daily ETF: Tradr 2X Long SRPT Daily ETF - Anticipated Liquidation/Anticipated Cash Settlement Option Symbol: SRPU
No comments yet — be the first to weigh in on SRPT.
Sign in to join the discussion.